CriticalOther antidepressants (NaSSA)×Selective irreversible MAO-B inhibitor
Updated · Methodology
Mechanism
Selegiline irreversibly inhibits monoamine oxidase type B (MAO-B) and belongs to the MAO inhibitors. At the dose recommended for Parkinson's disease, 5–10 mg a day, it acts selectively, but above 10 mg it may lose its selectivity (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Mirtazapine blocks central presynaptic alpha-2 adrenoceptors and so increases noradrenaline and serotonin transmission (mirtazapine SmPC, AEMPS). MAO inhibitors impair serotonin metabolism and, together with serotonergic antidepressants such as mirtazapine, raise the risk of serotonin syndrome (mirtazapine label, US Food and Drug Administration, FDA). The elimination half-life of mirtazapine is 20–40 hours, sometimes up to 65 hours (mirtazapine SmPC, AEMPS), and platelet MAO-B activity returns to normal about 2 weeks after selegiline (selegiline SmPC, AEMPS).
Symptoms
Serotonin syndrome may show as hyperthermia, rigidity, myoclonus, autonomic instability with rapid swings in vital signs, and mental changes ranging from confusion and irritability to extreme agitation, delirium and coma (mirtazapine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US mirtazapine label describes the syndrome as potentially life-threatening (mirtazapine label, US Food and Drug Administration, FDA). Post-marketing reports describe cases of serotonin syndrome, some of them fatal, in people who took selegiline together with antidepressants (selegiline orally disintegrating tablets label, FDA).
Management
The combination is contraindicated. The Spanish mirtazapine summary of product characteristics (SmPC) contraindicates mirtazapine with monoamine oxidase inhibitors (MAOIs) and makes no exception for MAO-B inhibitors (mirtazapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and selegiline is an MAO-B inhibitor by its own SmPC (selegiline SmPC, AEMPS). The US mirtazapine label contraindicates it in people who take an MAOI or stopped one less than 14 days ago and names selegiline among the examples (mirtazapine label, US Food and Drug Administration, FDA). The Spanish selegiline SmPC does not mention mirtazapine. The US label of selegiline orally disintegrating tablets advises avoiding its combination with any antidepressant (selegiline label, FDA). Start mirtazapine at least 2 weeks after stopping selegiline (mirtazapine SmPC, AEMPS; mirtazapine FDA label). Start selegiline about 2 weeks after stopping mirtazapine (mirtazapine SmPC, AEMPS), and not earlier than 14 days under the US label (mirtazapine FDA label). If serotonin syndrome develops, stop mirtazapine and start supportive symptomatic treatment (mirtazapine SmPC, AEMPS). The US label adds stopping all serotonergic drugs (mirtazapine FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Remeron/RemeronSolTab (mirtazapine) prescribing information (2025)– FDA, DailyMed, Remeron/RemeronSolTab, Organon LLC, setid 98ad1917-a094-44f5-a28f-a64a8cfcd887, revisión 08/2025, secciones 4, 5.3, 5.8, 7 y 12.3
- AEMPS: Ficha técnica de Rexer Flas 15 mg comprimidos bucodispersables (mirtazapina) (2021)– AEMPS, CIMA, nº registro 64819, revisión 04/2021, secciones 4.3, 4.5 y 5.1
- AEMPS: Ficha técnica: Selegilina, Plurimen 5 mg (nº registro 58113) (2026)– AEMPS, CIMA, nº registro 58113 (Plurimen 5 mg comprimidos), revisión 03/2026, secciones 4.3, 4.4, 4.5 y 5.1
- FDA: Zelapar (selegiline hydrochloride) prescribing information (2021)– FDA label, Bausch Health US, LLC, DailyMed setid 380d7717-2a79-42f3-a712-efe5e7696ba0, revised 06/2021, sections 4, 5.1 and 7.1
- AEMPS: Ficha técnica: Mirtazapina (nº registro 67068), sección 4.3 (2026)– AEMPS, CIMA, nº registro 67068, revisión 06/2026, sección 4.3